Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J. Morris, Howard I. Scher, Martin Gleave et al.|European Urology Oncology|2021Cited by 20
Erratum to “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)” [Eur Urol Oncol 2021;4:543–52]Michael J. Morris, Howard I. Scher, José Maurício Mota et al.|European Urology Oncology|2022Cited by 0